Actelion 2013 sales and earnings beat expectations
Switzerland-based Actelion (SIX: ATLN), Europe’s largest biotech firm, has reported financial results for full-year 2013, showing that product sales grew 6% (at constant exchange rates) to 1.78 billion Swiss francs ($1.97 billion).
Core earnings for the year reached 619 million francs, up 20% (CER) and net profit of 453 million francs, resulting core earnings per share of 4.41, up 20% at CER, and beating the average analyst estimate of 4.38 francs. Analysts in a Reuters poll had forecast product sales of 1.76 billion francs and net profit of 361 million francs.
Forward guidance
The company said it expected core earnings growth in the low single digits (CER) in 2014, in constant compared with a previous forecast for at least stable core earnings. It has also forecast core earnings growth in the single-digit range for 2015.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze